| Name | Title | Contact Details |
|---|
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.
Dialyze Direct provides staff assisted home hemodialysis services to elderly patients with End Stage Renal Disease who reside in Nursing Homes. Our mission is to deliver innovative and compassionate dialysis care to geriatric patients in Skilled Nursing Facilities, enhancing their quality of life while significantly reducing overall costs by improving outcomes, eliminating transportation and minimizing re-hospitalizations. The Dialyze Direct program permits an unprecedented degree of on-site coordination of care and sharing information with the nursing home staff, with respect to ESRD care, that include nursing, dietary and social work collaboration. Dialyze Direct has re-purposed home dialysis technology, with enhanced and proprietary protocols that are better suited to the special needs of geriatric patients with multiple co-morbid conditions resulting in improved outcomes, shortened recovery times, increased rehab score gains and decreased re-hospitalizations.
Gordon Stowe is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Cyrano team has developed a unique, proprietary intranasal product to restore function in patients with a chronic loss of taste and smell. This is a condition affecting at least 14 million people in the US and a similar number in Europe, having a significant impact on safety, quality of life and well-being.